Pituitary tumor transforming gene 1 (PTTG1) is expressed in most tumors. However, whether thyroid hormone (T 3 ) and its receptors (TR) regulate PTTG1 in human hepatocellular carcinomas (HCC) remains unclear. Previous cDNA microarrays revealed PTTG1 is down-regulated by T 3 /TR. This study investigated the significance of PTTG1 regulation by T 3 in HCC cells. The PTTG1 mRNA and protein expression were repressed by T 3 in HCC cell lines overexpressing TR. However, after knockdown of TRs expression by RNA interference, PTTG1 repression by T 3 was abolished. Similar results were observed in thyroidectomized rats. To localize the regulatory region in the PTTG1 promoter, serial deletions within the PTTG1 promoter region were constructed. The promoter activity of the PTTG1 gene was repressed (25-51%) by T 3 . Additionally, these findings indicate that PTTG1 may be regulated by Sp1. The critical role of the À594 and À520 Sp1 binding sites was confirmed by electrophoretic mobility shift assay. Transfection with Sp1 expression vector enhanced the activity of the PTTG1 promoter fragment reporter. Also, Sp1 was down-regulated in HCC cells and in thyroidectomized rat after T 3 treatment. Additionally, ectopic expression of PTTG1 promotes cell proliferation in Hep3B hepatoma cells. Conversely, knockdown of PTTG1 or Sp1 expression reduced cell proliferation in HepG2 cells. Notably, the expression of PTTG1 and Sp1 was inversely correlated with the expression of TR proteins in HCC. Together, these findings indicate that PTTG1 gene expression is mediated by Sp1 and is indirectly downregulated by T 3 . Finally, overexpression of PTTG1 or SP1 in HCCs is TR-dependent and crucial in the development of HCC.
Introduction
Thyroid hormone (T 3 ) regulates growth, development, and differentiation in vertebrates. Triiodothyronine binds to specific receptors (thyroid hormone receptors, TR), which belong to the superfamily of nuclear receptors. These receptors function as ligand-dependent transcription factors by binding to sequences known as thyroid hormone response elements (TRE), which are usually located in the promoter regions of target genes (1) . The human TRs are encoded by the TRa and TRh genes located on human chromosomes 17 and 3, respectively. By alternative splicing and different promoter usage, these two genes yield at least four proteins: TRa1, TRa2, TRh1, and TRh2 (2).
The liver is well recognized as a target organ for T 3 . Human hepatocytes express equal amounts of TRa1 and TRh1 proteins (3) . Normal human hepatocytes are difficult to maintain in vitro and become senescent soon after isolation. Therefore, T 3 regulation was examined in several human hepatoma cell lines. Using a cDNA microarray technique, this laboratory previously identified 148 genes positively regulated by T 3 in a TRa1 overexpressing hepatoma cell line (HepG2-TRa1). However, the other genes negatively regulated by TR were largely unexamined. Increasing evidence suggests that aberrant TR regulation or mutant TR genes may be associated with human neoplasia (4) . Previously, Lin et al. (5) reported truncated TRa1 and TRh1 cDNA in 53% of human hepatocellular carcinomas (HCC). A high incidence of multiple point mutations was observed in these mutated TRs. Other groups (6, 7) have reported mutated TRs in HCC and cultured cells. This study focused on a set of genes (i.e., oncogenes) normally repressed by TR but aberrantly induced because of reduced TR expression or mutation during carcinogenesis.
The pituitary tumor transforming gene 1 (PTTG1) is a multifunctional gene encoding a 23-kDa, 202-amino acid protein that induces cell transformation in NIH3T3 cells and tumor formation in nude mice (8) . Furthermore, PTTG1 is involved in liver regeneration (9) and is overexpressed in the hepatoma cell lines (10) . Additionally, previous microarray analysis showed that TR negatively regulated PTTG1. However, PTTG1 regulation by T 3 has not been fully characterized, and its pathogenic implications in hepatomas are largely unknown. This study therefore examined the transcriptional regulation of the PTTG1 gene by TR and its physiologic significance.
This study shows that T 3 down-regulates PTTG1 expression in HCC cells. Moreover, the promoter activity of the PTTG1 is repressed by T 3 . Serial deletion of the promoter and electrophoretic mobility shift assays (EMSA) were performed to locate the Sp1 sites on the PTTG1 promoter. Finally, the possible physiologic functions of such regulation were elucidated.
Materials and Methods
Cell culture. The human hepatoma cell lines HepG2, Hep3B, Huh7, J7, and Mahlavu were routinely grown in DMEM supplemented with 10% (v/v) fetal bovine serum. Serum was depleted of T 3 as described elsewhere (11) . Cells were cultured at 37jC in a humidified atmosphere of 95% air and 5% CO 2 .
Immunoblot analysis. Cell lysates were fractionated by SDS-PAGE on a 10% gel; the separated proteins were then transferred to a nitrocellulose membrane (Amersham), as described elsewhere (12) . Antibodies included rabbit polyclonal antibody to PTTG1 (Zymed) and Sp1 and Sp3 (Santa Cruz Biotechnology). C4, a mouse monoclonal antibody against TRa1 and TRh1, was a gift from Sheue-yann Cheng (National Cancer Institute).
Northern blot analysis. Total RNA was extracted from cells using Trizol reagent. Equal quantities of total RNA (20 Ag) were separated on a denaturing gel (1.2% agarose-formaldehyde gel) as described previously (13) .
The gel was then blotted onto a nitrocellulose membrane and subjected to Northern blot analysis, as described previously (12) .
Cloning the PTTG1 5 ¶ flanking region and promoter activity assay. Fragments of the PTTG1 promoter (nucleotides À2,512 to +52) were amplified via PCR according to the published nucleotide sequence (8) and then inserted into the pA3TK-Luc vector. Mutations of Sp1 binding sites were also constructed (DÀ620/À512). The promoter construct sequence was verified by automated DNA sequencing. To measure the influence of T 3 on the transcriptional activity of the PTTG1 promoter, HepG2-TRa1#1 cells (1 Â 10 5 per 12-well plate) were cotransfected via a Lipofectamine protocol using 1.2 Ag/well of pA3TK-luc vector containing PTTG1 promoter sequences (Invitrogen Corp.). The Sp1 expression plasmid was kindly provided by Hung, Jan-Jong (National Cheng Kung University). Cells were also cotransfected with 0.33 Ag of the h-galactosidase expression vector, pSVh plasmid (Clontech Laboratories, Inc.), as described elsewhere (12) .
Electrophoretic mobility shift assay. The PTTG1 promoter fragment (À620 to À512) was amplified and labeled with [a-
32 P] dCTP (3,000 Ci/ mmol; Amersham) via PCR for use as a probe. The PTTG1 promoter fragment (À925 to À817) served as a control. For the EMSA, an equal amount of in vitro-translated (Promega) Sp1 protein or nuclear extract (14) was incubated with [a-
32 P]-labeled PTTG1 fragments, as described elsewhere (13) . MOPC21, a mouse monoclonal antibody, was used as a negative control (Sigma-Aldrich).
Quantitative reverse transcription-PCR. Total cellular RNA was extracted by Trizol, as described elsewhere. Subsequently, cDNA was synthesized using the Superscript II kit for reverse transcription-PCR (RT-PCR; Life Technologies), as described previously (15) . Real-time quantitative RT-PCR (Q-RT-PCR) was conducted, as described previously (15) .
Experimental animals and human specimens. In accordance with techniques described elsewhere, thyroidectomy (Tx) was performed on two groups of 6-week-old male Sprague-Dawley rats (n = 10), and sham operations were performed on one group of 6-week-old male rats (n = 6; ref. Recombinant adenovirus and infection. The PTTG1 cDNA were subcloned into the XhoI site of the vector pAdTrack-CMV (16), a gift from B. Vogelstein (Johns Hopkins University). The resulting construct was sequenced, linearized, and cotransformed with pAdEasy1 into BJ5183 competent bacteria to generate recombinant pAdEasy1-PTTG1. Recombinant viruses were produced by transfecting linearized pAdEasy1-PTTG1 into 293 cells via a Lipofectamine method. Cells growing in log phase were infected with either empty or PTTG1 adenovirus for 40 h. Subsequently, the cell proliferation rate was assayed.
Establishing TRs/PTTG1/Sp1 knockdown stable HCC cell lines. The clones (V2HS_28556) of short hairpin RNA (shRNA) targeting PTTG1, and shRNA (NM_004219) for Sp1 were obtained from GENDISCOVERY (Open Biosystems). Additionally, the clone (TRCN000002039) of shRNA targeting TRa1 and the clone shRNA (TRCN0000020344) for TRb1 were purchased from National RNA Interference Core Facility (Institute of Molecular Biology, Academia Sinica). Transfection of shRNA for the targeting of endogenous PTTG1/Sp1/TRs genes was performed using Lipofectamine reagent (Invitrogen). After 24 h of incubation, cells were transferred to medium containing puromycin for selection. After 2 wk of selection, specific repression of the targeted gene was confirmed by Western blot analysis.
Detection of cell cycle phase by propidium iodide staining. Cells were harvested after 12 h of culture in the 6-cm dishes, washed once in PBS, centrifuged, and fixed in 70% ethanol for 24 h at 4jC. The nuclei were stained with propidium iodide (50 Ag/mL) after treatment with 0.5% Triton-X100/PBS containing 0.05% DNase-free RNase, and the DNA content was analyzed by flow cytometry using the fluorescence-activated cell sorting Aria cell sorting system (Becton Dickinson). The percentage of cells in each phase of the cell cycle was determined using the Modfit LT program (Verity Software House).
Cell proliferation assay. Cells (3 Â 10 3 ) were grown in a 96-well plate at 37jC with 5% CO 2 . At each time point, growth rate of cell was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method or by cell number counting. Absorbance was read at 570 nm, and background absorbance at 660 nm was subtracted in a Titertek Multiscan Plus MK1-ELISA reader (Labsystems and Life Sciences International Ltd.). Results are given in fold change of each control value.
Statistical analysis. Statistical analysis was carried out with the help of the Statistical Package for Social Science, version 13.0 (SPSS, Inc.).
Results
Effects of T 3 on PTTG1 mRNA and protein expression in HepG2 cells. In the four HepG2 cell lines investigated in this study (HepG2-TRa1#1, HepG2-TRa1#2, HepG2-TRh1, and HepG2-Neo), overexpression of TR protein was f10-fold, 3-fold, and 3.2-fold that of the HepG2-Neo control cell line (Fig. 1A) . Overexpressed PTTG1 protein and mRNA were compared between various HepG2 cell lines after incubation with or without T 3 for varying durations ( Fig. 1B and C) . The thyroid hormone T 3 suppressed expression of PTTG1 in HepG2-TRa1#1, HepG2-TRa1#2 (data not shown), and HepG2-TRh1 cells to a greater extent than in HepG2-Neo cells (Fig. 1B) . Protein levels in PTTG1 decreased 14% to 84% after incubation of HepG2-TRa1#1, HepG2-TRa1#2 (data not shown), and HepG2-TRh1 cells with T 3 (10 and 100 nmol/L) for 24, 48, and 72 hours, respectively. These experimental results show the timedependent properties of T 3 . However, the repression of PTTG1 by T 3 was maximized at f10 nmol/L (Fig. 1B) .
The effect of T 3 on the expression of PTTG1 mRNA was examined by Northern blot analysis. A 0.6-kb PTTG1 mRNA was detected in three examined cell lines (Fig. 1C) . Exposure of HepG2-TRa1#1 cells and HepG2-TRh1 cells to 10 and 100 nmol/L T 3 for 24, 48, and 72 hours, respectively, produced a dose-dependent decrease (63-87%) in PTTG1 mRNA. Furthermore, the repression by T 3 was almost maximal at 24 h. Additionally, the effect of T 3 on PTTG1 mRNA expression in HepG2-Neo cells was minimal (Fig. 1C) . These experimental results thus suggest that the effect of T 3 on PTTG1 protein expression is mediated, at least partly, at the transcription level.
Knockdown of TRs expression abolished repression of PTTG1 by T 3. To determine whether the PTTG1 repression is indeed TR dependent, TR protein expression was knocked down by RNA interference in four HCC cell lines. Huh7, J7, and Mahlavu expressed endogenous TRa1 and TRh1 proteins (Fig. 1A) . The small interfering RNA (siRNA) expression vectors encoding antisense TRa1 or TRh1 sequences and a control plasmid with a scrambled sequence were transfected into each cell line. Figure 1A depicts the expression of TR proteins in four TR knockdown (KD) and control (Neo) cell lines. The data indicate that RNA interference repressed the expression of almost all the TR proteins. Subsequently, the repression of Sp1 or PTTG1 by T 3 was diminished in the KD but not in the control Neo cell lines (Fig. 1D) . These experimental results show that TRs are a crucial determinant of T 3 repressive ability.
Localization of a negative regulatory region in the PTTG1 promoter. To further clarify the regulatory effect of T 3 on PTTG1 mRNA expression, cycloheximide, a protein synthesis inhibitor, was introduced. The effect of T 3 on PTTG1 mRNA expression in the presence or absence of cycloheximide was determined in HepG2-TRa1#1 cells. Blocking of protein repression with cycloheximide effectively abolished transcriptional repression of PTTG1 by 10 nmol/L T 3 . This experimental result suggests that the effect of T 3 on PTTG1 regulation may be indirect (data not shown). To determine whether the T 3 -induced repression of PTTG1 mRNA in HepG2 cells is mediated by an indirect effect of TR on PTTG1 transcription, the fragment of the PTTG1 promoter encompassing nucleotides À2,512 to +52 (relative to the translational initiation site) was cloned and inserted into a pA3TK-luc vector (containing a minimum thymidine kinase promoter). Serial truncated mutants of the PTTG1 promoter fragment (based on the À2,512/+52 construct; Fig. 2A) were also constructed and transfected into HepG2-TRa1 cells. The transcriptional activity of the À2,512/+52, À1,000/+52, and À1,000/À500 constructs was reduced by f45% to 58.5% in the presence of T 3 ( Fig. 2A) compared with the activity of the pA3TK-luc vector. To further delineate the promoter region involved in this marked inhibition of transcriptional activity by T 3 , the PTTG1 promoter sequences from nucleotides À1,000 to À500 were analyzed to identify binding sites from the transcription factor database (TFSEARCH: Searching Transcription Factor Binding Sites). This region includes two AP1 binding sites (À921 and À733), two Sp1 binding sites (À594 and À520), and one NF1 binding site (À511; Fig. 2B ). Additionally, computer analysis revealed no TREs in this PTTG1 promoter region. To further determine the pivotal nuclear transcription factor binding sites on the PTTG1 promoter regulated by T 3 , the promoter was further divided into seven fragments including À1,000/À553, À1,000/À595, À620/À553, À553/À487, À620/À512, À513/+52, and À500/+52. As Fig. 2A shows, T 3 reduced by 29.5% to 55% the promoter activity of only the À1,000/À553, À620/À553, À553/À487, and À620/À512 fragments (in HepG2-TRa1 cells; Fig. 2A ). Those fragments contain at Figure 1 . Thyroid hormone represses PTTG1 expression in HepG2 cell lines at the protein and mRNA levels. A, the TR protein expression level in four TR stable lines (HepG2-Neo, HepG2-TRa1#1, HepG2-TRa1#2, and HepG2-TRh1). Four HCC cell lines (Huh7, J7, Mahlavu, and HepG2-TRa1#1) were transfected with TRa1-specific or TRh1-specific RNA interference as described in Materials and Methods. Expression of TR proteins in four cell lines without (Neo) or with (KD) specific TR RNA interference transfection. PTTG1 expression was repressed by T 3 at protein (B ) or mRNA levels (C ). The TR stable lines were incubated with T 3 -depleted (Td ) medium in the absence or presence of 10 or 100 nmol/L T 3 for 24, 48, or 72 h. Cell lysates (100 Ag of protein) were then subjected to immunoblot analysis with polyclonal antibody to PTTG1. Alternatively, total RNA (20 Ag/lane) was then isolated and sequentially analyzed by Northern blot using the 32 P-labeled cDNA probe of PTTG1 and 18S rRNA. D, TR-dependent repression of PTTG1/Sp1 expression by T 3 . Cells were incubated with T 3 -depleted medium in the absence or presence of 10 nmol/L T 3 for 48 h. Cell lysates (100 Ag of protein) were then subjected to immunoblot analysis with polyclonal antibody to PTTG1 or Sp1. Actin was used as a loading control. least one Sp1 binding site. However, deletion of the Sp1 binding at À594 ( Fig. 2B ; À553/À487, Fig. 2A ) or À520 ( Fig. 2B ; À620/À553, Fig. 2A ) did not significantly affect the transcription repression activity of T 3 . Notably, transcription activity was induced rather than abolished completely when two Sp1 sites (À1,000/À595, À513/+52, À500/+52) were deleted. Furthermore, deletion of AP1 and NF1 binding sites (À620/À512) did not alter the repressive effect of T 3 on the PTTG1 promoter. However, the repression effect was diminished by mutation of these critical sites (DÀ620/À512). These experimental results strongly suggest the involvement of Sp1 or its related factor and show the important role of Sp1 in T 3 regulation of PTTG1 promoter activity. Taken together, our data indicate that the repression of PTTG1 promoter activity by T 3 is mediated by Sp1.
T 3 -reduced Sp1 expression in HepG2-TRA1 cells. Immunoblotting or Q-RT-PCR was performed to determine whether Sp1 or Sp1-related Sp2, Sp3, and Sp4 transcription factor is repressed by T 3 /TR and subsequently represses PTTG1 expression. Clearly, no T 3 repression of Sp2 or Sp4 was observed by Q-RT-PCR, whereas Sp3 expression was reduced after 72 h of T 3 treatment (Fig. 3A) . The Sp1 protein levels decreased f71.5% after incubation with 10 nmol/L T 3 for 48 hours. Furthermore, cells incubated in 100 nmol/L T 3 for 48 hours revealed slightly increased (88%) repression of Sp1 protein expression. Moreover, after 72 hours of incubation in 100 nmol/L T 3 , Sp1 expression was almost completely repressed (>90%; Fig. 3B ). Concomitantly, PTTG1 protein levels also decreased f70% to 85% after incubation of HepG2-TRa1#1 cells with 10 or 100 nmol/L T 3 for 48 or 72 hours (Fig. 3B) . However, this phenomenon was not observed in HepG2-Neo cells (Fig. 3C) .
Overexpression of Sp1 activates PTTG1 promoter activity. To clarify whether Sp1 is crucial in T 3 regulation of PTTG1 promoter activity, a Sp1 expression vector (in pcDNA3 vector) was cotransfected with the PTTG1 promoters noted in Fig. 2A . As  Fig. 4A shows, the transfection of Sp1 expression vector in T 3 -depleted as well as in 10 nmol/L T 3 medium increased PTTG1 promoter activity f4-fold to 6-fold in PTTG1 promoter fragments containing Sp1 (À1,000/+52, À1,000/À500, À1,000/À553, À620/ À553, À553/À487, and À620/À512) but had no effect on PTTG1 promoter fragments containing non-Sp1 or mutated Sp1 binding site (À1,000/À595, DÀ620/À512, À513/+52, and À500/+52; Fig.  4A ). These data indicate that overexpressed Sp1 may activate the PTTG1 promoter in HepG2-TRa1 cells with or without T 3 . Also, Sp1 apparently does not increase PTTG1 promoter activity if Sp1 binding sites have undergone mutation (DÀ620/À512).
To verify that Sp1 protein target Sp1 sites directly, a fragment containing two Sp1 sites was used as an EMSA probe. Reactions performed with [a- 32 P] labeled À620 to À512 fragment and in vitro-translated Sp1 protein produced one predominant band (Fig. 4B, lane 3) . Sp1 antibody (Fig. 4B, lane 4) but not control (Fig. 4B, lane 6) but not nonspecific cold probe (Fig. 4B, lane 7) . However, if the Sp1 binding sites in the À620 to À512 region mutated (DSp1), Sp1 binding activity was lost (Fig. 4B, lane 8 ). TR proteins with or without retinoid X receptor (RXR) did not bind to this region (Fig. 4B, lanes 9-14) . To further characterize whether TRa/h indirectly binds to PTTG1 promoter via complex formation with Sp1, supershift assay of the DNAprotein complex was performed using Sp1 antibodies (Fig. 4B, lanes  16, 20, 24 , and 28) or C4 (TRa/h; Fig. 4B, lanes 17, 21, 25, and 29) or control antibodies (MOPC21; Fig. 4B, lanes 18, 22, 26, and 30) . The results indicate that the complex was supershifted by Sp1 but not C4 antibody, and only Sp1 protein bound to the À620 to À512 fragment. Similar results were observed when HepG2 nuclear extracts were used (Fig. 4C) . Briefly, one predominant band was detected (Fig. 4C, lane 2 ) when using [a-32 P]-labeled À620 to À512 fragment. This band was specifically supershifted by the Sp1 antibody (lane 3) but not by the Sp3 antibody (lane 4) or C4 (lane 5) or the control antibody (lane 6). However, if using the mutated probe (DSp1), Sp1 binding activity was lost (Fig. 4C,  lane 7) . Additionally, the band could not be competed out by adding 10 times molar excess of nonspecific cold probe (Fig. 4C , lane 8) but by specific cold probe (Fig. 4C, lane 9) . These experimental results suggest that the factor binding to the À620 to À512 on PTTG1 promoter is Sp1-specific, but not Sp3-specific. The promoter assay and EMSA findings suggest that Sp1 activates PTTG1 gene transcription by directly binding to the Sp1 sites located between À620 and À512 bp (Fig. 4) .
T 3 represses PTTG1 and Sp1 protein expression in vivo.
Surgical Tx was performed in two groups of 6-week-old male Sprague-Dawley rats (n = 10 per group) to determine the in vivo responses of PTTG1 and Sp1 to T 3 treatment. One group (Tx + T 3 ) was injected with T 3 daily for 2 weeks; the second group (Tx) received no T 3 injections; the third group was sham-operated controls. The rats were sacrificed at the end of the experiment (4 weeks after thyroidectomized), and serum was collected for T 3 and TSH determination. The livers were removed for Western blot analysis. The T 3 serum levels in the Tx group were f0.022-fold (12.3 versus 548.1 ng/dL) than those in the group that received T 3 treatment (Tx + T 3 ). Levels of TSH in the Tx group were f67.2-fold (2.42 versus 0.036 ng/mL) than those of the T 3 -treated group. The T 3 and TSH serum levels in the sham group were f48.1 ng/dL and 0.197 ng/mL, respectively. Western blot analysis showed that repression of PTTG1 and Sp1 protein levels in the Tx + T 3 group were 76% and 61%, respectively, that of the Tx group. The PTTG1 and Sp1 protein levels in the sham group were 32% and 28%, respectively, that of the Tx group (Fig. 5A) .
Furthermore, the clinicopathologic significance of PTTG1 expression in HCC was also investigated. In total, 65 patients with HCC were consecutively selected for this study. An equal amount (100 Ag) of protein from each specimen was loaded for electrophoresis and Western blot analysis. Equal loading was confirmed by Coomassie blue staining after SDS-PAGE (data not shown). The PTTG1 and Sp1 proteins were detected in most of the cancerous tissues. The results from 23 representative paired HCC specimens are shown in Fig. 5B , indicating the increased PTTG1/Sp1 expression and the concomitantly decreased TR protein expression in Figure 5 . The PTTG1 was regulated by TR through Sp1 in both thyroidectomized rats and human HCC specimens. A, repression of PTTG1 and Sp1 expression by T 3 in rat livers. Expression of PTTG1 protein in sham, Tx (thyroidectomized), or Tx + T 3 male Sprague-Dawley rat livers was determined by Western blot analysis, as described in Materials and Methods. Intensities of PTTG1 and Sp1 bands on blots were quantified. Actin was used as a loading control. Values are shown as fold induction of the control (Tx) group, and differences were examined using the Student t test. Columns, mean of values from three independent experiments (n = 10 rats per group); bars, SE. **, P < 0.01; *, P < 0.05. B, reduced TR expression and overexpression of Sp1/PTTG1 protein in 23 representative pairs of human HCC specimens. T, tumor tissue; N, noncancerous adjacent tissue. Equal loading was confirmed by Coomassie blue staining after SDS-PAGE (data not shown). (Fig. 5B) .
Knockdown of Sp1 or PTTG1 expression inhibits HepG2-TRA1 cell growth. To further study PTTG1 function in HCC, PTTG1 expression was repressed by siRNA. The siRNA expression vectors encoding antisense PTTG1 sequences and a control plasmid with a scrambled sequence were transfected into HepG2-TRa1 cells. Figure 6A depicts the expression of PTTG1 in two HepG2-TRa1 knockdown (PTTG1 KD#1 and PTTG1 KD#2; lanes 2 and 3) and one control (HepG2-TRa1-Neo; lane 1) stable cell line. Additionally, Sp1 knockdown (Sp1 KD#1 and Sp1 KD#2; Fig. 6A , lanes 5 and 6) and control (HepG2-TRa1-Luc; lane 4) stable cell lines were prepared. Reduced Sp1 concomitantly suppressed PTTG1 expression (Fig. 6A, lanes 5 and 6) , demonstrating that Sp1 is specifically down-regulated by T 3 and subsequently decreases PTTG1 expression in HepG2-TRa1 cells. The two PTTG1-knockdown stable lines (#1 and #2), as well as the two Sp1 KD stable lines (#1 and #2) grew significantly (P < 0.01) more slowly than did the control HepG2-TRa1-Neo or HepG2-TRa1-Luc cell lines (Fig. 6B) , suggesting that PTTG1 or Sp1 positively regulates cell proliferation.
Ectopic overexpression of PTTG1 promotes cell proliferation in Hep3B hepatoma cells. The Hep3B cells expressing low levels of endogenous PTTG1 were infected with adenovirus encoding PTTG1. After 40 hours of infection, PTTG1 expression in infected cells was determined. Figure 6A shows that PTTG1 expression in two Hep3B-PTTG1 sublines (#1 and #2; Fig. 6A , lanes 9, 10) was higher than in noninfected cells or in cells infected with control GFP vector (Fig. 6A, lanes 7 and 8) . To determine the effect of PTTG1 overexpression in Hep3B cells, cell proliferation was determined by MTT assay or cell number counting (data not shown) at 24 to 120 h after adenovirus-PTTG1 infection. The adenovirus-PTTG1-infected cells exhibited significantly higher proliferation rates than uninfected cells or cells infected with control GFP vector, whereas cell proliferation was very similar in both control cells (Fig. 6C) . These experiments indicate that overexpression of PTTG1 can induce cell proliferation in Hep3B hepatoma cells. 
Discussion
This study characterized PTTG1, which was previously identified in cDNA microarray screening for T 3 -responsive genes in HepG2-TRa1 cells. The regulation of PTTG1 by T 3 and the significance of this regulation in HCC have not been reported. This study examined the molecular mechanism of PTTG1 regulation by T 3 in isogenic HepG2 cell lines and its physiologic significance. The experimental results indicate that PTTG1 regulation by T 3 is indirect and mediated by Sp1. Further study showed that T 3 downregulates Sp1 expression. Additionally, exogenous transfection of Sp1 expression vector into HepG2-TR cells increased PTTG1 promoter activity. Furthermore, promoter activity analysis showed that two important Sp1 sites at À594 and À520 upstream of human PTTG1 participate in T 3 -induced change in human PTTG1 gene transcription. Observation of a similar regulatory process observed in thyroidectomized rat specimens is consistent with these findings. Notably, the expression of PTTG1 and Sp1 was inversely correlated with the expression of TR proteins in HCCs. Moreover, the experimental data clearly show that negative regulation of PTTG1 by T 3 is mediated by reduced Sp1 expression. Transcription factors other than Sp1, such as NF-Y, also regulate PTTG1 expression (17) . Both Sp1 and NF-Y are essential in the transcriptional regulation of the human PTTG gene. However, the regulation of NF-Y by T 3 was not observed (data not shown); therefore, NF-Y is not involved in T 3 repression. Furthermore, T 3 had a minimal effect on the quantity of PTTG1 mRNA in HepG2-Neo cells. Knockdown of TRs expression abolished the repression of PTTG1 by T 3 . Thus, the effect of T 3 on PTTG1 protein repression is apparently TR-dependent and mediated, at least partly, at the mRNA level. Ying et al. (18) and Furuya et al. (19) reported that PTTG1 is physically associated with TRh1 or mutant TRh1 in vivo. Additionally, PTTG1 directly interacts with the ligand-bound TRh1 and with the steroid receptor coactivator-3 that recruits a proteasome activator (PA28g). Subsequently, association with the above-mentioned complex induced the degradation of PTTG1 in association with the wildtype TRh1-dependent receptor but not the mutant receptor. However, this study shows that the reduced expression of PTTG1 was largely due to down-regulation of Sp1 by T 3 . The experimental results of this study extend and supplement those of Ying et al. The PTTG1 is largely down-regulated at the transcriptional level according to the current findings. The remainder is regulated at the protein level as reported by Ying et al.
Overexpression of PTTG1 enhances the cell proliferation, migration, invasion, and/or tumorigenicity of cells derived from cancers of the human pituitary, esophagus, breast, thyroid, lung, head, and neck, as well as uterine leiomyomas, glioma, and pituitary adenomas (20) (21) (22) (23) (24) (25) (26) (27) (28) . Earlier studies indicate that T 3 significantly suppresses the growth of HepG2-TR overexpressing cells (29) . However, T 3 repression was not observed in the control cell line (HepG2-Neo), which did not express detectable TR. The suppressive effect is mediated at least partly by down-regulation of PTTG1 observed in this study because overexpression of PTTG1 is associated with cell proliferation, angiogenesis, and poor prognosis in HCC (30) . After all, the expression of PTTG1 is very low in normal cells.
The Sp1 protein plays an important role in the growth and invasion of cancer cells (31, 32) . The overexpression of Sp1 is often negatively associated with survival rates in several cancers (33, 34) . Sp1 has been reported to be overly expressed in gastric cancer tissue and negatively expressed in adjacent noncancerous tissue (35) . The Sp1 protein is the major transcription factor of several genes associated with proliferation or invasion (36) . Recently, Tong et al. (37) indicated that PTTG1 apparently interacts with Sp1, and full-length PTTG1 positively regulates Sp1 activity. Additionally, Sp1 regulates PTTG1. Tong et al. therefore proposed the existence of an auto-feedback mechanism between Sp1 and PTTG1.
Consistent with previous reports (36, 38) , the overexpression of PTTG1 in HCC in this study was observed with concomitant overexpression of Sp1 in vitro, as well as in vivo. Moreover, Sp1, but not Sp2, or Sp4 was also negatively regulated by T 3 at protein and mRNA levels. Therefore, TRs may play a suppressor role by reducing PTTG1 and Sp1 expression in normal liver. However, when TRs expression is reduced in HCC, TRs lose their tumor suppressor role during hepatocarcinogenesis. Thus, alleviation of repression leads to induction of PTTG1 or Sp1 overexpression. However, in some cases, the inverse correlation was not observed because of possible deletion or mutation of TR genes (5).
Nevertheless, the precise mechanisms of this phenomenon require further study. In conclusion, this investigation showed that overexpression of PTTG1 or Sp1 in some HCCs is TR dependent and might play a crucial role in the development of HCC (39) . Also, ligand-activated TR indirectly transactivates PTTG1 gene transcription through critical Sp1 binding sites located within the 5 ¶ flanking region of the gene. Moreover, alteration of PTTG1 expression through overexpression by adenovirus or through underexpression by siRNA causes changes in cell proliferation. Clearly, a suppressor role of TR during liver carcinogenesis can be postulated.
